Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 5, 2011, Pages 567-575

  Pinilla, I ^a   Gomez Leon N ^a   Del Campo Del Val, L ^b   Hernandez Maraver, D ^a   Rodriguez Vigil B ^a   Jover Diaz R ^c   Coya, J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Lymphoma; Neoplasm staging; Positron emission tomography; Tomography, X ray computed

Indexed keywords

DIATRIZOATE; FLUORODEOXYGLUCOSE F 18; IOBITRIDOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTERNAL CAROTID ARTERY ANEURYSM; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOPLASMOCYTIC LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; ONCOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; PYELONEPHRITIS; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SPLENIC MARGINAL ZONE LYMPHOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DIATRIZOATE MEGLUMINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIATION DOSAGE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84856140491     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hicks RJ, Mac Manus and Seymour JF. Initial staging of lymphoma with positron emisión tomography and computed tomography. Semin Nucl Med 2005;35:165-75 (Pubitemid 41149006)
2. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003;30: 117-27
3. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79. (Pubitemid 30643379)
4. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system:initial results. Radiology 2002;225:575-81. (Pubitemid 35239264)
5. Bar-Shalom R. Normal and abnormal patterns of FDG-PET/CT in lymphoma. Radiol Clin N Am 2007;45:677-88.
6. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KDM, von Schulthess GK et al. Non-Hodgkin lymphoma and hodgkin disease: reregistered FDG PET and CT at staging and restaging - do we need contrast enhanced CT? Radiology 2004;232:823-9. (Pubitemid 39100269)
7. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of fdg pet and ct findings in patients with lymphoma: initial experience. Radiology 2005;237:1038-45. (Pubitemid 41636398)
8. La Fougère C, Hundt W, Bröckel N, Pfluger T, Haug A, Scher B et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. E J Nucl Med Mol Imaging 2006;33:1417-25. (Pubitemid 44885407)
9. Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DHS et al. Comparison between 2-deoxy-2[18F] fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004;6:411-6. (Pubitemid 39618921)
10. Raani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?. Ann Oncol 2006;17:117-22. (Pubitemid 43033850)
11. Elstrom RL, Leonard JP, Coleman M, Brown RKJ. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 2008;19:1770-3.
12. Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008;49:1693-701.
13. Wiley, G. Disruptive technology:the conflict over PET/CT. Imaging economics 2005;1:1-10.
14. Rodríguez-Vigil B, Gómez-León N, Pinilla I, Hernández-Maraver D, Coya J, Martín-Curto L et al. PET/CT in lymphoma prospective study of enhanced full-dose pet/ct versus unenhanced low-dose PET/CT. J Nucl Med 2006;47:1643-8. (Pubitemid 47545030)
15. Pfannenberg AC, Aschoff P, Brechtel K, Müller M, Klein M, Bares R. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol 2007;80:437-45. (Pubitemid 47322230)
16. Morimoto T, Tateishi U, Maeda T, Arai Y, Nakajima Y, Kim E. Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways:Comparison of integrated PET/CT with or without contrast enhancement. E J Radiol 2008;67:508-13.
17. Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002;81:20-5. (Pubitemid 36075491)
18. Ansquer C, Hervouët T, Devillers A, de Guibert S, Gastinne T, Le Gouill S et al. 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. Haematologica. 2008;93:128-31.
19. Fuertes S, Setoain X, López-Guillermo A, Montserrat E, Fuster D, Paredes P et al. Utilidad de la tomografía por emisión de positrones/tomografía computarizada (PET/TC) en el estudio de extensión en pacientes con linfoma B difuso de células grandes. Med Clin 2007;129:688-93. (Pubitemid 350256396)
20. Miller E, Metser U, Avrahami G, Dvir R, Valdman D, Sira LB et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patientsComput Assist Tomogr. 2006;30:689-94.
21. La Fougère C, Pfluger T, Schneider V, Hacker M, Bröckel N, Morhard D et al. Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined [18F]-FDG PET/CT. Nuklearmedizin. 2008;47:37-42. (Pubitemid 351272809)
22. Freudenberg LD, Antoch G, Schütt P, Beyer T, Jentzen W, Müller SP et al. FDG-PET in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325-9.
23. Altamirano J, Esparza JR, de la Garza Salazar J, Sobrevilla Calvo P, Rivas Vera S, Chalapud Revelo JR et al. Staging, Response to Therapy, and Restaging of Lymphomas with 18 F-FDG PET. Arch Med Res 2008;39:69-77. (Pubitemid 350192011)
24. Pakos EE, Fotopoulos AD, Ioannidis JPA. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphomas meta-analysis. J Nucl Med 2005;46:958-63. (Pubitemid 43733510)
25. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U et al. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical managementQ J Nucl Med Mol Imaging 2008;52:9-16. (Pubitemid 351351040)
26. Muslimani AA;Faraq HL, Francis S, Spiro TP, Chaudhry AA, Chan VC et al. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol 2008;31:409-12.
27. Elstrom E, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6. (Pubitemid 36857861)
28. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma:the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007;34:60-7. (Pubitemid 44885555)